Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)184.40
  • Today's Change2.90 / 1.60%
  • Shares traded278.90k
  • 1 Year change+174.49%
  • Beta0.6169
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

  • Revenue in EUR (TTM)5.45bn
  • Net income in EUR240.00m
  • Incorporated--
  • Employees9.08k
  • Location
    Ucb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
  • Phone+32 25599999
  • Fax+32 25599900
  • Websitehttps://www.ucb.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sandoz Group AG-106.55bn-106.55bn18.88bn23.85k--2.36----------17.03------------------------0.7401--0.3469--7.23---90.92------
Astellas Pharma Inc10.83bn334.62m18.98bn14.75k56.402.0112.391.7530.4230.42986.34854.610.50601.363.39120,113,500.001.564.592.316.6181.7880.533.097.980.862315.320.377486.615.604.19-82.73-40.179.6213.00
Zhangzhou Pientzhng Phrmctcl Co Ltd1.42bn400.19m19.95bn2.79k49.8610.95--14.085.105.1018.0823.240.64011.6714.663,911,417.0018.2218.8222.5123.9143.9146.5528.4627.983.64--0.074736.4915.6916.1113.1519.6013.8331.06
Biogen Inc8.96bn1.51bn23.53bn7.57k15.641.5311.142.6211.0711.0765.83112.900.340.86044.581,269,155.005.7112.537.0114.8375.5983.0416.8026.930.80394.890.27780.00-3.32-6.07-61.89-23.58-18.87--
Bayer AG47.11bn-1.27bn23.66bn96.57k--0.66293.360.5021-1.29-1.2947.9636.330.39011.473.47472,438.70-1.04-1.79-1.42-2.3858.0759.02-2.67-4.800.85732.940.5651---6.115.33-170.87--1.19-47.66
Otsuka Holdings Co Ltd13.87bn926.46m32.38bn34.39k33.982.0520.142.33279.51279.514,183.344,641.150.6472.404.6865,998,690.004.424.805.595.8871.4268.216.848.361.53--0.117342.1616.149.33-9.188.079.271.92
Alnylam Pharmaceuticals, Inc.1.95bn-309.99m33.38bn2.10k--1,104.79--17.08-2.62-2.6216.520.25110.52083.578.41997,521.40-8.26-26.56-11.31-32.7785.3783.66-15.86-94.262.69-1.360.9694--76.2389.4561.08---13.29--
UCB SA5.45bn240.00m35.87bn9.08k149.893.9138.406.581.231.2327.9247.190.35181.714.26600,462.401.555.031.886.2867.8072.214.4012.660.78063.150.253436.44-4.802.54-18.33-15.41-1.512.36
Haleon PLC13.55bn1.46bn39.66bn24.00k17.25--174.952.930.21060.21061.44--------468,333.30--------61.94--11.21----7.59----4.09---1.04------
Takeda Pharmaceutical Co Ltd27.79bn1.77bn41.03bn49.28k23.190.96646.401.48181.90181.902,862.684,365.910.30881.316.2592,248,190.001.971.652.351.9766.0568.056.386.060.77393.080.4219128.425.8715.25-54.561.2829.090.8735
Jiangsu Hengrui Pharmaceuticals Co Ltd3.38bn708.05m41.04bn19.61k58.247.21--12.150.84990.84994.066.860.571.574.601,325,555.0011.9413.6812.9915.2084.8885.8720.9420.018.34--0.00223.777.265.5510.141.1422.909.45
Sun Pharmaceutical Industries Ltd5.56bn1.22bn48.00bn43.00k39.246.2831.728.6346.1246.12209.89288.060.60051.054.1511,699,470.0013.297.7716.9210.8579.1571.5922.1414.232.09--0.035838.6410.5110.7813.0129.15-7.2837.47
Data as of Nov 08 2024. Currency figures normalised to Ucb SA's reporting currency: Euro EUR

Institutional shareholders

24.82%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 03 Oct 202415.94m8.19%
Wellington Management Co. LLPas of 14 May 202412.75m6.56%
The Vanguard Group, Inc.as of 02 Oct 20244.38m2.25%
Norges Bank Investment Managementas of 30 Jun 20243.33m1.71%
BlackRock Fund Advisorsas of 03 Oct 20242.67m1.37%
Capital International Ltd.as of 03 Oct 20242.57m1.32%
BlackRock Investment Management (UK) Ltd.as of 29 Oct 20242.11m1.09%
Artisan Partners LPas of 30 Sep 20241.56m0.80%
Eleva Capital SASas of 30 Jun 20241.53m0.79%
BlackRock Advisors (UK) Ltd.as of 03 Oct 20241.42m0.73%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.